Early-Stage Lung Cancer

Annual lung cancer screening, or LCS, detects cancer at a higher rate and at earlier stages, findings suggest.

Among patients with stage IA non-small cell lung cancer, long-term survival was better with lobectomy or segmentectomy vs. wedge resection, according to results presented at the Society of Thoracic Surgeons Annual Meeting.

The FDA approved alectinib as an adjuvant treatment for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer following tumor resection and detection by an FDA-approved test.

Adjuvant therapy with alectinib prolonged DFS compared with platinum-based chemotherapy for certain patients with lung cancer, according to the agent’s manufacturer.

CHICAGO — The addition of pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab improved outcomes for patients with early-stage resectable non-small cell lung cancer, according to findings presented at ASCO Annual Meeting.

Patients with early-stage non-small cell lung cancer who underwent surgical resection had higher rates of long-term survival than those who received stereotactic body radiation therapy, according to study results.

Patients who received sublobar resection for early-stage non-small cell lung cancer had similar 5-year DFS rates compared with those who underwent lobectomy, according to results of a randomized phase 3 study.

Although use of limited resection or stereotactic body radiation therapy for early-stage non-small cell lung cancer had comparable odds for at least one adverse event, the overall toxicity profiles differed, according to study results.

Ravi Salgia, MD, PhD, spoke with Healio about a study assessing the safety and efficacy of three cycles of neoadjuvant sintilimab plus platinum-doublet chemotherapy compared with two cycles in patients with early-stage lung cancer.